121 related articles for article (PubMed ID: 11073849)
1. Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapy.
de Man FH; Jonkers IJ; Schwedhelm E; Smelt AH; Onkenhout W; van Duyvenvoorde W; Buytenhek R; Leuven JA; Troost R; van Der Laarse A; Princen HM
Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2434-40. PubMed ID: 11073849
[TBL] [Abstract][Full Text] [Related]
2. The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding.
de Man FH; de Beer F; van der Laarse A; Jansen H; Leuven JA; Souverijn JH; Vroom TF; Schoormans SC; Fruchart JC; Havekes LM; Smelt AH
Atherosclerosis; 2000 Dec; 153(2):363-71. PubMed ID: 11164425
[TBL] [Abstract][Full Text] [Related]
3. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.
Eisenberg S; Gavish D; Oschry Y; Fainaru M; Deckelbaum RJ
J Clin Invest; 1984 Aug; 74(2):470-82. PubMed ID: 6378975
[TBL] [Abstract][Full Text] [Related]
4. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
Winocour PH; Durrington PN; Bhatagnar D; Ishola M; Mackness M; Arrol S; Anderson DC
Atherosclerosis; 1992 Mar; 93(1-2):83-94. PubMed ID: 1596307
[TBL] [Abstract][Full Text] [Related]
5. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.
Jonkers IJ; Smelt AH; Hattori H; Scheek LM; van Gent T; de Man FH; van der Laarse A; van Tol A
J Lipid Res; 2003 Aug; 44(8):1462-9. PubMed ID: 12754275
[TBL] [Abstract][Full Text] [Related]
6. [Effects of plasma very low density lipoprotein, low density lipoprotein and high density lipoprotein on platelet aggregation in endogenous hypertriglyceridemia].
Deng Z; Liu B; Zhou J; Zhang Z; Liu Y; Bai H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):704-7. PubMed ID: 14619587
[TBL] [Abstract][Full Text] [Related]
7. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
Waysbort J; Schwartz S; Brunner D
Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
[TBL] [Abstract][Full Text] [Related]
8. Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a 'procoagulant state': effects of bezafibrate therapy.
Jonkers IJ; de Man FH; van Tilburg NH; van der Laarse A; Sandset PM; Smelt AH; Bertina RM
Blood Coagul Fibrinolysis; 2001 Dec; 12(8):705-12. PubMed ID: 11734672
[TBL] [Abstract][Full Text] [Related]
9. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
[TBL] [Abstract][Full Text] [Related]
10. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
Jonkers IJ; Mohrschladt MF; Westendorp RG; van der Laarse A; Smelt AH
Am J Med; 2002 Mar; 112(4):275-80. PubMed ID: 11893366
[TBL] [Abstract][Full Text] [Related]
11. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
[TBL] [Abstract][Full Text] [Related]
12. Plasma very-low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein oxidative modification induces procoagulant profiles in endogenous hypertriglyceridemia.
Bai H; Liu BW; Deng ZY; Shen T; Fang DZ; Zhao YH; Liu Y
Free Radic Biol Med; 2006 May; 40(10):1796-803. PubMed ID: 16678017
[TBL] [Abstract][Full Text] [Related]
13. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
[TBL] [Abstract][Full Text] [Related]
14. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
[TBL] [Abstract][Full Text] [Related]
15. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.
Jonkers IJ; Smelt AH; Princen HM; Kuipers F; Romijn JA; Boverhof R; Masclee AA; Stellaard F
J Nutr; 2006 Apr; 136(4):987-91. PubMed ID: 16549462
[TBL] [Abstract][Full Text] [Related]
16. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
Norioka M; Suzuki M; Ryomoto K; Ikebuchi M; Harano Y
J Atheroscler Thromb; 2000; 7(4):198-202. PubMed ID: 11521682
[TBL] [Abstract][Full Text] [Related]
17. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
18. Abnormal composition of hypertriglyceridemic very low density lipoprotein determines abnormal cell metabolism.
Sehayek E; Eisenberg S
Arteriosclerosis; 1990; 10(6):1088-96. PubMed ID: 2244857
[TBL] [Abstract][Full Text] [Related]
19. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
Gavish D; Oschry Y; Fainaru M; Eisenberg S
Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
[TBL] [Abstract][Full Text] [Related]
20. Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus.
Yamaguchi T; Shirai K; Nagayama D; Nakamura S; Oka R; Tanaka S; Watanabe Y; Imamura H; Sato Y; Kawana H; Ohira M; Saiki A; Shimizu N; Tatsuno I
J Atheroscler Thromb; 2019 Jul; 26(7):659-669. PubMed ID: 30584220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
